NCT01771458 2025-11-24
SHIVA
Institut Curie
Phase 2 Completed
Clinical Trials
15 trialsNCT02492711 2025-03-17
SOPHIA
MacroGenics
Phase 3 Completed
NCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT02213289 2021-04-08
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
University of Chicago
Phase 2 Completed
NCT01285466 2020-12-09
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
Phase 1 Completed
NCT01271920 2020-12-08
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
Novartis
Phase 1/2 Completed
NCT01295086 2020-11-02
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
Odense University Hospital
Phase NA Completed
NCT01396707 2020-01-07
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
Asan Medical Center
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01472029 2017-06-19
HerFLOT
AIO-Studien-gGmbH
Phase 2 Completed
NCT02721641 2017-03-31
A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02100917 2015-02-10
Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults
Meiji Seika Pharma Co., Ltd.
Phase 1 Completed
NCT01235897 2014-04-17
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
University of California, San Francisco
Phase 1 Completed
NCT01603264 2012-12-18
A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
Pfizer
Phase 1 Completed
NCT00031278 2011-05-30
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Pfizer
Phase 1/2 Completed